Interview18 Nov 2018 12:32
I'm sure TM intimated in a recent interview that he thought IMM was currently undervalued by the market. He also stated that he would never argue with the market, and everything balances out eventually.
So as far as I am concerned there is no need for IMM to issue an RNS in response to this rise in sp, it's just the balancing TM referred to, and I do not believe the balancing has finished. Huge upward momentum of the sp right into the close on Friday, so much so that this could quite easily 'pop' to the late 20's on Monday - which is still 50% up from current sp.
Wish I could find the interview - anyone know?
"However, what could make the business interesting at its current price is that, by writing off Lupuzor™ as a failure, the market may have missed the drug’s superior response rate and its robust safety profile."